Eiger BioPharmaceuticals Inc (STU:72C) Stock Price, Trades & News

Eiger BioPharmaceuticals Inc is a commercial stage biopharmaceutical company focused on the development and commercialization of drugs for serious, rare, and ultra-rare diseases with high unmet medical needs and no approved therapies. Its program lonafarnib, a prenylation inhibitor, boosted with ritonavir, for the treatment of Hepatitis Delta Virus (HDV) infection, is in Phase 3 clinical development. Its product candidate pipeline includes Lonafarnib (LNF) in HDV, Peginterferon Lambda (lambda) in HDV, LNF in Progeria, and Progeroid Laminopathies (PL), Avexitide in Post-Bariatric Hypoglycemia (PBH), and Avexitide in Congenital Hyperinsulinism (CHI), all advancing toward Phase 3.

Financial Strength

	Name	Current	Vs Industry		Vs History

Growth Rank

	Name	Current	Vs Industry		Vs History

Momentum Rank

	Name	Current	Vs Industry		Vs History

Liquidity Ratio

	Name	Current	Vs Industry		Vs History

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History

Profitability Rank

	Name	Current	Vs Industry		Vs History
	FCF Margin %	-1174.36
	OCF Margin %	-1170.68

GF Value Rank

2/10

	Name	Current	Vs Industry		Vs History

Financials (Next Earnings Date:2026-08-27 Est.)

Annual Quarterly TTM

STU:72C's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Eiger BioPharmaceuticals Inc Executives

Details

GF Value™

STU:72C

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected issues with 72C. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	5.863
	EPS (TTM) (€)	-10.647
	Beta	1.8748
	3-Year Sharpe Ratio	-0.29
	3-Year Sortino Ratio	-0.37
	Volatility %	-
	14-Day RSI	-
	14-Day ATR (€)	-
	20-Day SMA (€)	6.18
	12-1 Month Momentum %	-
	52-Week Range (€)	6.18 - 6.18
	Shares Outstanding (Mil)	1.48

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	0
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Eiger BioPharmaceuticals Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Eiger BioPharmaceuticals Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-10	In 124 days
Third quarter earnings results for 2026	2026-11-10	In 124 days
Second quarter earnings conference call for 2026	2026-08-27	In 49 days
Second quarter earnings results for 2026	2026-08-27	In 49 days
First quarter earnings results for 2026	2026-07-08	6.18 (+0.00%)
General meeting for 2025	2026-07-08	6.18 (+0.00%)
First quarter earnings results for 2025	2025-05-15	6.18 (+0.00%)
General meeting for 2024	2025-04-15	6.18 (+0.00%)
Annual report for 2024	2025-04-08	6.18 (+0.00%)
Third quarter earnings results for 2024	2024-11-08	6.18 (+0.00%)

Show

Entries

Eiger BioPharmaceuticals Inc Frequently Asked Questions

What is Eiger BioPharmaceuticals Inc(STU:72C)'s stock price today?

The current price of STU:72C is €6.18. The 52 week high of STU:72C is €6.18 and 52 week low is €6.18.

When is next earnings date of Eiger BioPharmaceuticals Inc(STU:72C)?

The next earnings date of Eiger BioPharmaceuticals Inc(STU:72C) is 2026-08-27 Est..

Does Eiger BioPharmaceuticals Inc(STU:72C) pay dividends? If so, how much?

Eiger BioPharmaceuticals Inc(STU:72C) does not pay dividend.

Press Release

	Subject	Date
	Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of Hutchinson-Gilford Progeria Syndrome from Eiger BioPharmaceuticals	2024-05-03
	Eiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	2024-01-18
	Eiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock Split	2024-01-04
	Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update	2023-11-14
	Eiger to Discontinue Phase 3 LIMT-2 Trial of Peginterferon Lambda in Patients with Chronic Hepatitis Delta	2023-09-12
	Eiger BioPharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference	2023-09-05
	Eiger BioPharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update	2023-08-14
	Eiger BioPharmaceuticals to Focus on Metabolic Diseases with Avexitide; David Apelian Takes Helm as CEO	2023-06-29
	Eiger BioPharmaceuticals to Host Business Update Call Tomorrow	2023-06-28
	Eiger BioPharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update	2023-05-11

10/Page

Articles on Eiger BioPharmaceuticals Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.